Can strong GLP-1 drug sales fuel Eli Lilly stock?

Traders Union
All News
Stocks
Eli Lilly jumps 6.87% after earnings

Highlights

Eli Lilly reported third-quarter 2026 revenue of $24.4 billion, up 39% year over year on strong sales of GLP-1 drugs Mounjaro and Zepbound.
Full-year 2026 revenue guidance rose to $91 billion to $92 billion, indicating management expects continued business strength.
Shares of Eli Lilly surged 6.87% and trade between $1,280 and $1,396, with technicals showing bullish momentum but possible short-term exhaustion signs.

Earnings beat and GLP-1 demand drive revenue forecast higher

Eli Lilly reported third-quarter 2026 revenue of $24.4 billion, a 39% increase from the previous year driven by exceptionally strong sales performance, according to Qz. The company raised its full-year 2026 revenue guidance to a range of $91 billion to $92 billion, signaling management's expectation of sustained business momentum. Demand for its GLP-1 drugs Mounjaro and Zepbound continued to accelerate revenue growth, as highlighted by CNBC, while a new 52-week high was achieved following the earnings beat and raised forecast, Marketbeat reported.

Mixed technical signals as intraday momentum faces exhaustion risk

The hourly chart shows LLY/USD above the MA-20 at $1,283 and the MA-50 at $1,284, and it is well above the MA-200 on the daily chart at $1,088. The Ichimoku Kijun sits at $1,278, acting as immediate support. MACD signals Buy, while ADX remains Neutral, suggesting trend strength is not yet decisive. RSI stands at 53.48 (Buy), but Stochastic RSI issues a Sell signal. Both CCI and Bull/Bear Power indicate overbought conditions and strong buyer dominance intraday. The Awesome Oscillator is Neutral, yielding a mixed signal profile, with momentum and oscillator divergences reflecting both persistent buying and the risk of short-term exhaustion.

Upside bias persists as price nears pivotal resistance range

Over the next 2 to 3 trading days, LLY is projected to move within a $1,280 to $1,396 range, reflecting the typical volatility band relative to current levels. There is a 71% probability of the price continuing upward within this band, and a 29% chance of a down move. Should the price break above $1,396, an extension of the uptrend is likely; conversely, a slip below $1,280 could prompt a short-term correction.

Viktoras Karapetjanc, expert at Traders Union, sees strong fundamental momentum in Eli Lilly following an exceptional 39% revenue jump and upgraded guidance. He notes that surging demand for GLP-1 drugs and robust sentiment after the earnings beat are driving the stock’s new highs. Technicals and macro backdrop together suggest sustained upside within the prevailing range. "With fundamentals so firmly bullish and demand surging, I expect Eli Lilly to extend its advance as long as $1,280 holds as support."

Earlier, analysts noted that Eli Lilly was trading in a consolidation pattern, with technical and institutional developments indicating a gradual upward bias unless a decisive breakout occurred. The latest earnings-driven surge and elevated revenue guidance strengthen the outlook for sustained momentum, making the $1,396 level a critical point to monitor for potential further gains or short-term exhaustion in the coming sessions.

Source of Data: LLY Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

The information is based on forecasts and does not constitute investment advice or a guarantee of future results. Market conditions may change. See our Disclaimer and Editorial Integrity for details.